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Reduced in vitro binding of tryptophan by plasma in uremia.
Since markedly depressed binding of the essential amino acid
tryptophan to plasma proteins of fasting chronically uremic
patients was previously shown, we have now determined the
association constants (k) and binding sites (n) for tryptophan for
whole plasma and purified albumin from normal subjects and
patients on intermittent hemodialysis. We used the in vitro equi-
librium dialysis technique (plasma: buffer ratio =1:25) and
analyzed the data by computer with a one ligand-two binding
sites model. Over a wide range of free tryptophan concentra-
tions (0.26 to 10 mg/100 ml), binding was markedly depressed in
the patients. The diminution was mainly due to a decrease of n1
(binding capacity of the strong, first site on albumin) from the
normal value of 0.74±0.14 (SD) to 0.52±0.15 (P<0.025). The
k1 of 4.1 1.1 for the patients and 4.6±0.7 x 10 L/M for normal
subjects were not different. In four of eight patients, binding of
tryptophan at the second site was 20% of the total at low trypto-
phan concentrations. In contrast, binding indexes of albumin
isolated from four patients by (NH4)2S04 fractionation plus
DEAE-Sephadex column chromatography were identical to those
of albumin similarly isolated from three normal controls. We
conclude that abnormal binding of tryptophan in uremia is
probably not due to an intrinsic defect of albumin but to the
presence of a competing solute, which is either a nondialyzable
large molecule or a small solute which binds extremely tightly to
albumin. On the other hand, the possibility was not excluded
that abnormal albumin was present in vivo but was either lost or
"normalized" during the purification procedure. This abnorm-
ality may also be the basis for the observed reduced binding of
many drugs, particularly of the acidic type, to plasma proteins in
chronically uremic patients.
Diminution in vitro de Ia liaison du tryptophane au plasma au
cours de l'urémie. II a été montré antérieurement une diminution
importante de Ia liaison du tryptophane aux protéines plasma-
tiques des sujets a jeün atteints d'urémie chronique. Nous avons
déterminé les constantes d'association (k) et les sites de liaison (n)
du tryptophane au plasma total et a l'albumine purifiée de sujets
normaux et de sujets soumis a l'hemodialyse iterative. Nous avons
utilisé Ia technique de Ia dialyse a l'équilibre (rapport plasma!
tampon =1,25) et analyse mathématiquement les résultats pour
un modèle a un ligand et deux sites de liaison. Pour un large
éventail de concentration de tryptophane libre (0,26 10 mg/
100 ml), Ia liaison est nettement diminuée chez les malades. La
diminution est due essentiellement a Ia baisse de n1 (capacité de
liaison du premier Site fort sur l'albumine) d'une valeur normale
de 0,74±0,14 (SD) 0,52±0,15 (P<0,025). Les k1 de 4,1±1,1
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des malades et de 4,6 0,7 x I 0 L/M des norniaux ne sont pas
différents. Chez quatre des huite malades Ia liaison du trypto-
phane au deuxiéme site est de 20% du total aux concentrations
faibles de tryptophane. A l'opposé, les paramétres de liaison de
l'albumine isolée chez quatre malades par fractionnement avec
(NH4)2 SO4 et chromatographie sur colonne de DEAE-Sephadex
sont identiques a ceux de l'albumine isolée de la même facon
chez trois sujets témoins. Nous concluons que Ia liaison anor-
male du tryptophane au cours de l'urémie n'est probablement
pas due a un deficit intrinsCque de l'albumine mais a Ia presence
d'un solute compétiteur qui est soit une grosse molecule non
dialysable soit une petite molecule qui se lie fortement a l'albu-
mine. D'autre part, Ia possibilité n'est pas exclue d'une albumine
anormale presente in vivo et perdue ou "normalisée" durant Ia
purification. Cette anomalie peut aussi être Ia base de la diminu-
tion observée de Ia liaison de divers mCdicaments, particulière-
ment du type acide, aux protéines plasmatiques chez des malades
atteints d'urémie chronique.
Depressed concentrations of amino acids, particu-
larly among the essential group, were found in patients
with far-advanced chronic renal failure. In our ex-
perience, these changes were not reversed in many
patients despite intermittent dialysis therapy for nine
months or longer [1, 2]. Of the essential amino acids in
plasma, the concentration of tryptophan was most
severely depressed in the patients both before and
while receiving intermittent hemodialysis therapy.
These observations on the total concentrations of
tryptophan in plasma required further analysis because
tryptophan is the only amino acid which is bound to
plasma proteins, specifically to albumin, only 25%
normally being in the free or unbound form [3]. There-
fore, we studied the binding of tryptophan to plasma
proteins in normal subjects and patients receiving in-
termittent dialysis, using the ultrafiltration technique.
We showed a striking depression of the binding of
tryptophan to plasma proteins in the patients [2]. We
felt that this abnormality deserved further characteri-
zation for several reasons. First, the metabolic disposi-
tion of tryptophan may be affected by the abnormal
binding. Second, tryptophan is the limiting amino acid
in the liver for synthesis of albumin [4], the plasma
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concentration of which is often depressed in uremic
patients. Third, the abnormal binding of tryptophan
to albumin is part of a more general abnormality in
uremia, since binding of diphenylhydantoin, digitoxin
and sulfonamides are also impaired [5—8].
In the present studies, we attempted first to deter-
mine whether the abnormal binding of tryptophan was
due to a competing, dialyzable solute in the plasma of
uremic patients. We, therefore, used the in vitro equili-
brium dialysis technique with a large plasma to buffer
ratio. By using a wide range of tryptophan concentra-
tions in these studies, we also determined the associa-
tion constant (k) and the number of binding sites (n)
for tryptophan in whole plasma. Finally, because some
studies have suggested the presence of abnormal sub-
forms of albumin in uremia [6], we isolated and puri-
fied albumin from uremic patients and normal sub-
jects and examined the binding characteristics of tryp-
tophan to the purified albumin.
Methods
Subjects. We studied six women and two men with
chronic renal failure who ranged in age from 29 to 60 yr
(mean, 43 yr). All patients were dialyzed three times
weekly with a coil-type artificial kidney. The patients
had been on dialysis from 1 to 29 months before the
study. The only medications being taken were alumi-
num hydroxide, folic acid and, for some patients,
ferrous sulfate. All patients were in fairly good nutri-
tional condition with a mean (± SD) plasma albumin
concentration of 3.25 0.47 g/l00 ml. The serum of all
patients was negative for hepatitis-associated antigen
and none had any evidence of chronic liver disease.
Informed consent was obtained from all patients.
We studied three male and three female normal con-
trols who ranged in age from 22 to 44 yr (mean, 34 yr).
All were in good health. No drugs were taken for a
minimum of one month before the study. The mean
serum creatinine concentration was 1.05±0.02 mg/
100 ml and the mean plasma albumin concentration
was 4.31 0.25 g/l00 ml.
After an overnight fast, blood was drawn in the
morning into heparinized test tubes for the binding
studies on whole plasma or without anticoagulant for
the binding studies with purified albumin. About 40 ml
of blood was taken from the patients on the morning
before a dialysis and 60 ml was taken from the control
subjects. The blood was centrifuged and the plasma
decanted for immediate study. Some plasma samples
were frozen at —50°C for no more than five days be-
fore study. Control experiments with the same plasma
studied either immediately or after being frozen for
ten days showed identical results. The unheparinized
samples were allowed to clot at room temperature for
two to three hours, centrifuged and the serum de-
canted.
Isolation of albumin. Between 9 and 13 ml of serum
was brought to 55% saturation with (NH4)2S04 and
centrifuged. The supernatant was dialyzed for 24 hr at
4°C against three changes of a 5-liter bath of distilled
water and then for 2 hr at room temperature against
2 liters of a 0.1M Tris chloride buffer of pH 8.0. This
material was then applied to a 25 x 0.9 cm column of
DEAE-Sephadex-A25 which had been previously equi-
librated with the Tris buffer. Three buffers, each at
pH 8.0, were used for eluting the sample in a stepwise
sequence. The buffers were 0.1M Tris chloride, 0.1M
Tris chloride+0.3M NaCl and 0.lM Tris chloride+
0.5M NaCI. Five-ml fractions were collected. Between
50 and 75 ml of each buffer were used for elution. All
the material coming down with the second buffer (the
bulk of the material) and most of the long tail eluted
with the third buffer (until the O.D. 280 fell below 0.1)
were collected and dialyzed for 24 hr at 4°C against
four changes of a 5-liter distilled water bath. The
dialyzed protein solution was then flash-evaporated to
10 ml and lyophilized. By standard cellulose acetate
electrophoresis [2], this material was found to consist
of albumin with a trace contamination of x1-globulin.
For binding studies with this material, solutions of
1.27 to 2.45 g/100 ml were made using the appropriate
buffer and concentrations of tryptophan.
Equilibrium dialysis. Cellophane tubing of 7/16 inches
flat width was used. The inside of the tubing was
washed with several rinses of distilled water, then
soaked in several changes of a 4-liter bath of distilled
water for 48 to 72 hr at 4°C. The tubing was cut every
20 cm and each bag was double-knotted at one end
with gloved hands, gently inflated with air, knotted at
the other end and allowed to dry overnight. The bags
were then cut at the single-knotted end, filled with 1 ml
of plasma or albumin solution, tied 1 cm above the
plasma level with two miniature size cable ties (Cable
Tie Panduit Corp., Tinley Park, IL) and dipped into
25 ml of dialysis bath. The basic composition of the
bath was as follows: sodium, 116 mEq/liter; potas-
sium, 5 mEq/liter; calcium, 2.3 mEq/liter; magnesium,
1.2 mEq/liter; chloride, 135 mEq/liter; sulfate, 1.2
mEq/liter; and Tris-Tris Cl 30 mmoles/liter. The pH of
this buffer was 7.4 at 37°C. For each plasma binding
study ten different L-tryptophan concentrations were
used ranging from 0.013 to 4.9 mmoles/liter, a 383-
fold range. To each 50-ml dialysis flask (Pyrex screw-
cap test tube) was added 6.7 x 10- Ci of L-trypto-
phan-1-'4C in 25 l of water. For the binding curves
using purified albumin, concentrations of L-tryptophafl
ranged from 0.019 to 0.377 mmoles/liter. Each flask
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with a different tryptophan concentration was made in
duplicate. The flasks were mounted on a wheel rotating
at 45 rpm and inclined at an angle of 45°. The equili-
brium dialysis was conducted for five hours at 37±
1°C, since preliminary studies showed that tryptophan
was fully equilibrated by this technique. At the end of
the dialysis, the bags were removed from the bath and
blotted. One-half ml of the bag content and 1 ml of the
corresponding bath were dissolved in a scintillation
fluid (Instagel, Packard Instrument Co.) and counted
in a liquid scintillation spectrometer (Tricarb, Packard
Instrument Co.). Appropriate corrections were made
for quenching using an internal standard. The albumin
content of the bags was measured by an electrophoretic
method as previously published [2], using either a
pooi of aliquots from three bags after dialysis or on a
pool of an aliquot taken out of each bag. This proce-
dure was used to correct for changes in albumin con-
centration (6 to 9 %) occurring during the dialysis
period. The total tryptophan in undialyzed plasma
samples was measured by a modification of the method
of Hess and Udenfriend [9]. Creatinine in plasma was
measured with an autoanalyzer (Technicon).
The specific activity of each dialysis flask was deter-
mined from the sum of the dpm recovered out of the
bag content and from the external buffer divided by
the total amount of tryptophan inside the bag before
dialysis plus the tryptophan added to the bath. The
concentration of 'tC in the bath was taken as the dpm/
ml of free tryptophan, the concentration of 14C in the
bag as the dpm/ml of total tryptophan. The dpm/ml of
bound tryptophan = total—free. Absolute concentra-
tions of tryptophan after dialysis were calculated from
the dpm/ml and specific activity. The mol wt of albu-
min was assumed to be 65,000. No correction was
made for Donnan effect. No electrostatic correction
was applied.
Analysis of data. When we analyzed our data with a
standard Scatchard plot [10], a curved line was obtained
indicating that a more complex model was required.
On further analysis the data were found to fit closely a
modification of the equation derived by Feldman [11]
for one ligand and two sets of binding sites:
n + n2F
-+F -+F
moles of ligand bound/literwhere V =
moles of protein/liter
F = free (unbound) ligand concentration,
n1 = number of binding sites of the first set,
= association constant for the first set of
binding sites,
number of binding sites of the second set
and
k2 = association constant for the second set of
binding sites.
The indexes k1, k2, n1 and n2 were used to draw two
straight lines, the sum of which results in the observed
binding curve. Analyses were made with the a com-
puter (Burroughs 6700) at the University of California,
Davis, Curve fitting was tried using three different
minimization methods: conjugate gradient, random
search and the method of BMDX 85 from the Univer-
sity of California, Los Angeles. The procedure of
BMDX 85 was chosen because of its ease in handling,
although all three methods gave the same results. For
each individual study, BMDX 85 was used to fit our
model and to determine n1, n2, k1, k2 for the V/F vs.
V plot. The same indexes were also analyzed for the
data of all control subjects taken as one group and for
all the patients taken as a second group. The indexes
n1, n2, k1 and k2 were given appropriate constraints.
Various starting values were tried in range of the con-
straints and the resulting answers were the same. This
finding indicates mathematically that we were achiev-
ing the best possible approximations to our constants.
Graphing was done using a plotter (Cal—Comp).
As the slopes of the binding curves for the patients
and the control subjects were roughly the same, we
used Wilcoxon's rank sum test, which is a nonpara-
metric statistical test, to evaluate the difference be-
tween the Y intercepts of the binding curves of the con-
trol subjects and the patients. Student's t test was also
used for the Y intercept and for the other binding in-
dexes.
Reagents. L-tryptophan was purchased from Sigma
Chemical Company, St. Louis MO, and used without
further purification. L-tryptophan-l-'4C was obtained
from Calbiochem, Los Angeles with a specific activity
of 9.6 mCi/mmole. This material was purified by
ascending chromatography for 16 hr on paper
(Whatman 3M) using a butanol-acetic acid-water
(4—1—5) solvent mixture. The L-tryptophan spot was
eluted with water, and when rechromatographed in the
same system, 98.8% of the counts recovered were
located in the L-tryptophan region. The bovine albu-
min standard was from Technicon Corp., New York.
All other chemicals were reagent grade.
Results
The total fasting plasma tryptophan concentration
was 0.94 0.11 mg/lOO ml (mean SD) for the normal
subjects and 0.57 0.12 for the patients (P<0.00l).
Figs. 1 and 2 give the Scatchard plots for representa-
tive studies on whole plasma from a normal subject
and a patient, respectively. The hyperbolic solid lines
through the data points were graphed by the Cal—Comp
plotter using the binding indexes for the model given
under Methods as obtained by the BMDX 85 pro-
gram. The hyperbolic line is the sum of the derived
equations for the two binding sites, which are repre-
sented by the dashed and dash-dotted lines. The
intercepts on the X axis of the dashed and dash-
dotted lines in Figs. 1 and 2 equal n1 and n2, the maxi-
mum number of moles of tryptophan per mole of albu-
min which can be bound to the first and second binding
sites, respectively. The slopes of the lines equal —k1
and —k2, the association constants. The intercepts on
theY axis equal n1.k1 and n2.k2.
The point closest to the Y axis in each figure repre-
sents the equilibrium dialysis study at an identical bath
concentration of 0.26 mg/100 ml of tryptophan, the
average free tryptophan concentration in normal fast-
ing plasma. The ratio of bound tryptophan (expressed
as moles of tryptophan per mole of albumin=) to free
tryptophan (=F) of 3.5 in the normal subject is 1.7
times larger than the ratio in the uremic patient. The
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Fig. 1. Scatchardplot of the binding of L-tryptophan to plasma of
a normal individual (subject 1). In this and all other figures
V= moles/liter of bound tryptophan/mole/liter of albumin;
F= moles/liter of free tryptophan; the dashed line (— — —) is the
computed first component of the binding curve; the dash-dot
line (— —•) is the computed second component of the binding
curve. Each solid circle is the mean of duplicate determinations.
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Fig. 2. Scatchard plot of the binding of L-tryptophan to plasma of
a patient (subject 2). See Fig. 1 for explanation of symbols.
reduced binding of the patient's plasma is seen through-
out the initial steep portion of the whole plasma bind-
ing curve.
Table 1, which gives the data for all studies on whole
plasma, shows that the average value for n1 of 0.52 for
the patients was significantly reduced below the average
normal value of 0.74. By contrast, the average associa-
tion constant of the first binding site (k1) for the
patients was not significantly different from normal.
The indexes for the second binding site are given in
the third and fourth columns of Table 1. It should be
noted that the scatter of the data for n2 and k2 is con-
siderably greater than for n1 and k1. This difference is
inherent in the method, since the calculation of bound
tryptophan (total —free) becomes increasingly inaccu-
rate at very high concentrations of free tryptophan as
the percent bound becomes a smaller and smaller per-
cent of the total tryptophan in plasma. The intercepts
on the Y axis of the straight lines represent n1 .k1 and
k2, respectively, and the intercept of the solid
hyperbolic line represents n1 .k1 + n2 k2. These inter-
cepts also represent the extrapolated maximum ratios
of V/F at extremely low concentrations of the ligand,
tryptophan. Table I shows that n1k1+n2•k2 is signi-
ficantly reduced in the patients. For the normal sub-
jects n2 k2 makes a negligible portion of the n1 .k1+
n2•k2 sum. By contrast, for some patients the n2.k2
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Table 1. Binding indexes for L-tryptophan to plasma proteins of the control subjects and of the patients
n1 k1 n2 k2 n1k11' na.kae nik+nakad
Mean 0.74
Control subjects (N= 6)
4.6 10.3 0.08 3.34 0.18 3.52
Mean 0.52
Patients (N= 8)
4.1 6.0 0.27 2.04 0.35 2.40
t=2.68
P<0.025
Significance
t=0.94 t=0.73 t=l.61
P>0.5 P>0.5 P>0.1
t=4.76
P<0.OOl
t=2.0
P>0.05
t=4.35
P>0.Ol
a To obtain absolute values, all terms containing k1 or k2 should be multiplied by 10g.
Y intercepts on the Scatchard plot of the computed first components.
Y intercepts on the Scatchard plot of the computed second components.
' Y intercepts on the Scatchard plot of the experimental whole plasma binding curves. Using the Wilcoxon's rank sum test, the Y inter-
cepts of the whole plasma binding curves are different comparing the control subjects and the patients at the 99% confidence level.
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Fig. 3a, b, c, d. Comparison of Scatchard plots of the binding of L-tryptOphan to whole plasma and to purijied
albumin from four patients (subjects 2 through 5). See Fig. 1 for explanation of symbols.
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product appears to be an appreciable fraction (roughly
20%) of the n,•k,+n2.k2 sum.
Fig. 3 shows the binding curves for the purified
albumin of four uremic patients compared with the
corresponding binding curve for whole plasma and the
computed first component of the binding curve for
whole plasma. The data for purified albumin were
analyzed as straight lines because the fit was excellent
in each case and because we did not have data at very
high concentrations of tryptophan.
Purification of albumin from the three patients with
the most abnormal binding curves (Fig. 3b, c, d) re-
sulted in a marked improvement to normal of all the
binding indexes. The changes in indexes due to puri-
fication were significant (P<O.05) using the paired
t test. By contrast, purification of albumin from three
normal controls did not alter any of the binding in-
dexes, using the same statistical method.
Fig. 4 shows the Scatchard plot for the binding
studies on purified albumin from the patients and the
normal subjects. Since the data clearly fit a straight
line for each group, we first determined two regression
lines, one for the patient group and one for the normal
subjects. Statistically, there was no difference in either
slopes or Y intercepts of the two lines. We, therefore,
combined all the data and determined the overall re-
gression equation as given in the figure. The close
similarity between the regression line of Fig. 4 for
purified albumin and the computed first component
for whole plasma of the normal subjects (Table 1)
should be noted. The slopes are —4.2 vs. —4.6 and the
Y intercepts are 3.21 and 3.34, respectively.
Discussion
In the present study, total plasma tryptophan con-
centrations of patients with minimal renal function on
intermittent hemodialysis were significantly depressed
below normal, confirming our earlier work done on a
different population of patients at another institution
[2]. The reduced plasma albumin concentration
accounts in part for the low total plasma tryptophan
concentration. However, the results of the equilibrium
dialysis studies point toward an additional abnormality
of a qualitative nature, i.e., reduced binding capacity
of the plasma albumin of patients as illustrated in
Figs. 1 and 2. These binding plots show that at a given
value of V (moles of tryptophan bound per mole of
albumin) on the horizontal axis, the value of V/F (ratio
of albumin-bound tryptophan to free tryptophan) is
lower in the patient than in the normal subject. In
other words, it takes a higher concentration of free
tryptophan in the patient compared to the normal to
achieve an equal degree of tryptophan binding per
mole of albumin. This reduced binding ability was
seen over a very wide range (0.26 to 10 mg/100 ml) of
free tryptophan concentrations.
Because the Scatchard plots were obviously curvi-
linear, the mathematical analysis of the data (Table 1)
was done using a model of one ligand-two binding
sites, the model which on preliminary analysis best fit
the data.' This analysis showed that on the average
the maximum binding capacity (n,) of the first binding
site is significantly reduced in the patients. This site
accounts for virtually all bound tryptophan in normal
subjects at physiological levels of the ligand but for a
lesser amount (about 80%) in one-half of the patients.
By contrast, the affinity constant of the first binding
site (k1) was on the average not different from normal.
Several possible explanations for the reduced bind-
ing capacity at the principal site (n,) on albumin must
be considered. There might be accumulation in chronic
renal failure of a solute which binds to albumin and,
by changing the conformation of the molecule, reduces
1 A two ligand-one binding site model was not consistent with
the data since in this model the line for the second (unknown and,
therefore, unmeasureable) ligand is below the horizontal axis
[11].
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Fig. 4. Scatchard plot of the binding of L-tryptophan to purified
albumins. See Fig. 1 for explanation of V and F. Triangles repre-
sent data from four patients (subjects 2 through 5), shown in-
dividually in Fig. 3a, b, c, d. Solid circles represent data from
three normal subjects (6 through 8). Each symbol is the mean of
duplicate determinations. y=3.2l —4.22X, r= —0.93, P<0.0O1.
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n1. The equilibrium dialysis studies were carried out
for five hours with a 25: 1 ratio of buffer to plasma.
That dialysis of small solutes, which was extremely
efficient by this method, was verified by finding that
the creatinine concentration of the plasma from
patients was reduced to an average of 0.2 mg/100 ml
after the in vitro dialyses. Therefore, if a retained
solute caused the abnormal binding, it would either
have to be a large, nondialyzable compound (e.g.,
peptide or protein) or a small solute with an extremely
high association constant, i.e., virtually all bound to
albumin. There is no data in this study or in the litera-
ture bearing on the first possibility. None of the small
solutes known to be retained in renal failure fulfill the
second criteria. One class of substances which are
tightly bound to albumin and displace bound trypto-
phan is the fatty acids [12, 13]. The concentration of
total free fatty acids in chronically uremic patients is
usually normal [14, 15]. However, different fatty acids
have a wide range of affinities for albumin [12]. It
would be of interest to know what the concentrations
of specific free fatty acids are in plasma and, particu-
larly, on the albumin of uremic patients, but we are not
aware of any such data.
The effect of heparin, used for anticoagulation dur-
ing dialysis, needs to be considered, as it is an activator
of lipoprotein lipase. All the blood samples were
drawn at least 40 hr after the discontinuation of
dialysis and heparin. Any effect of heparin should have
disappeared long before samples were drawn for the
studies.
Another possibility is that the albumin molecule
itself is intrinsically abnormal in uremia due to faulty
synthesis or a chemical change produced secondarily.
Microheterogeneity of bovine and human albumin has
been described, although firm proof that more than
one form of the monomer exists in vivo has not been
published to our knowledge [16, 17]. On the basis of
limited data, the depressed binding of digitoxin and
diphenylhydantoin to uremic plasma has been attri-
buted to a change in such subtypes of albumin [6].
Our studies with purified albumin (Figs. 3 and 4) make
this possibility rather unlikely for the case of trypto-
phan binding. Purification of albumin by ammonium
sulfate fractionation and DEAE-Sephadex column
chromatography restored the binding of tryptophan
by albumin to normal. As shown in Fig. 3d, the binding,
capacity of even the most abnormal plasma was fully
corrected by our purification method.
On the other hand, the data do not exclude the possi-
bility that an abnormal albumin was present in vivo but
was either lost or "normalized" during the purifica-
tion procedure. We used standard methods for isola-
tion of albumin, which in normal subjects yields albu-
mm of a high degree of purity at a high recovery. How-
ever, as we did not measure actual recovery rates, this
possibility deserves further study. Likewise, the possi-
bility that, in contrast to findings with normal plasma
components [18], uremic globulins or large mol wt
peptides are the locus of at least part of the weak bind-
ing at very high concentrations of tryptophan deserves
investigation.
The depressed binding of tryptophan by the first
binding site in uremic plasma was partly offset by en-
hanced binding by the second binding site. This fact
can be appreciated either by the graphical method de-
veloped by Rosenthal [19] or by use of the funda-
mental binding equation (see Methods). Using data
from Table 1 and this equation, one can calculate the
free tryptophan concentration when 50% of the
bound tryptophan is located on each binding site
(i.e., equal distribution). The free tryptophan con-
centrations at this point of equal distribution of bound
tryptophan at the two binding sites was 7.3 x 10
moles/liter for the normals and 0.8 x 10 for the
patients. The location of the second binding site is not
known. The finding of a curvilinear Scatchard plot for
binding of tryptophan to bovine albumin fragments by
King and Spencer [20] suggests that it may be on albu-
min; however, more direct studies on human plasma
proteins are needed to be certain.
Our values in normal subjects for n1 and k1 differ
somewhat from those of McMenamy et al. For human
plasma they found a value of 1.0 for n1 and 6 x 10 for
k1 [3]. By predialyzing the plasma before doing the
binding studies, they found a k1 of 12 x 10, comparable
to the association constant of pure mercaptalbumin for
tryptophan [18]. Since their methods differed from
ours in many aspects, we cannot determine the causes
of these differences. However, since in our experiments
plasma samples from control subjects and patients
were studied under exactly the same conditions, the
comparison of data from our two groups should be
valid.
It is interesting to speculate on the possible clinical
consequences of abnormal protein binding in uremia.
Depressed binding in uremic plasma of a number of
drugs, including sulfonamides, digitoxin and diphenyl-
hydantoin, has been reported [6—8]. In the case of
diphenylhydantoin, this abnormality has significant
clinical consequences, since the tj- value of disappear-
ance of this drug is shortened by nearly one-half in
uremic patients [21].
In our earliest studies of total plasma tryptophan,
the very low plasma concentrations in patients with
advanced renal failure led us to suggest that trypto-
phan deficiency might exist and play a role in the pro-
tein depletion (hypoalbuminemia, muscle wasting)
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often found in such patients [9]. It is possible that in
patients maintained on rigid protein restriction for
prolonged times the free, as well as total tryptophan,
concentration might be depressed. We have not investi-
gated such patients as yet. However, our more recent
[2] and present findings in patients on intermittent
dialysis who were in reasonably good nutritional state
raise other possibilities. In patients on intermittent
dialysis, the fasting concentration of free tryptophan
in plasma was significantly elevated. Under some cir-
cumstances, tryptophan is the limiting amino acid for
synthesis of albumin [4]. It is possible that elevated
free concentrations of the amino acid are required to
achieve normal rates of albumin synthesis.
The elevated free tryptophan concentrations in the
dialyzed patients could have deleterious effects. Slight
elevation of plasma-free tryptophan concentrations by
direct or indirect means [13, 22, 23] leads to an increase
in brain content of serotonin in the rat. This response
seems to be due to the fact that substrate is rate-limit-
ing for the enzyme tryptophan hydroxylase. Disturb-
ances of central nervous system function are prominent
in uremia. Since serotonin may have an active role in
multiple functions of the brain [24], the possibility of
altered metabolism of this important amine in uremia
deserves investigation.
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